

CITATION REPORT

List of articles citing

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

DOI: 10.1016/s0140-6736(89)92442-2
Lancet, The, 1989, 1, 1036-8.

Source: <https://exaly.com/paper-pdf/20884054/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
443	Disease assessment in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1989 , 48, 962	2.4	2
442	Antimalarials in rheumatic diseases. 1990 , 4, 467-89		46
441	The use of sulphasalazine as a disease modifying antirheumatic drug. 1990 , 4, 535-51		9
440	Combination therapy in rheumatoid arthritis. 1990 , 4, 663-85		4
439	Resolve: methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis. 1990 , 20, 76-80		24
438	Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine. 1990 , 19, 407-12		43
437	Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. <i>Lancet, The</i> , 1990 , 335, 539	4.0	48
436	Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow?. 1990 , 30, 501-10		17
435	The rheumatoid wrist: patterns of disease progression. A review of 50 wrists. 1991 , 16, 275-9		16
434	The Gold Standard in Rheumatoid Arthritis. 1991 , 84, 513-514		1
433	Combination chemotherapy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1991 , 50, 507-9	2.4	5
432	Disease modification in rheumatoid arthritis with special reference to cyclosporin A. 1992 , 95, 19-28		
431	Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1992 , 51, 424-9	2.4	15
430	Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine. <i>Annals of the Rheumatic Diseases</i> , 1992 , 51, 946-50	2.4	58
429	Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1992 , 51, 177-81	2.4	217
428	The course of rheumatoid arthritis. 1992 , 6, 1-21		20
427	The course and outcome of rheumatoid arthritis. Radiological measures of outcome. 1992 , 6, 39-67		2

426	Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. 1992 , 35, 26-34		341
425	Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. 1992 , 35, 849-56		91
424	Antirheumatic drugs: a proposed new classification. 1993 , 36, 336-9		59
423	Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. 1993 , 36, 1501-9		114
422	Amyloidosis—incidence and early risk factors in patients with rheumatoid arthritis. 1993 , 22, 158-61		36
421	Clinical pharmacokinetics of slow-acting antirheumatic drugs. 1993 , 25, 392-407		67
420	Clinical management of rheumatoid arthritis. <i>Lancet, The</i> , 1993 , 341, 286-90	40	42
419	Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?. <i>Annals of the Rheumatic Diseases</i> , 1993 , 52, 423-8	2.4	24
418	A T cell receptor beta chain variable region polymorphism associated with radiographic progression in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1993 , 52, 327-31	2.4	13
417	Medical management of rheumatoid arthritis. 1993 , 307, 425-8		8
416	Outcome of second line therapy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1994 , 53, 812-5.4		19
415	Prediction of radiographic damage in hands and feet in rheumatoid arthritis by clinical evaluation. 1994 , 13, 487-91		6
414	Second-line drug therapy for rheumatoid arthritis. 1994 , 330, 1368-75		136
413	Effects of strength training on neuromuscular function and disease activity in patients with recent-onset inflammatory arthritis. 1994 , 23, 237-42		76
412	Reclassification of Antirheumatic Agents. 1994 , 1, 110-116		6
411	Do Disease-Modifying Antirheumatic Drugs Actually Modify Disease Course in Rheumatoid Arthritis?. 1994 , 1, 319-322		4
410	Comparison of intramuscular gold and sulphasalazine in the treatment of early rheumatoid arthritis. A one year prospective study. 1995 , 24, 330-5		13
409	Tropical rheumatology. Treatment issues. 1995 , 9, 231-45		

408	Advances and issues in the pharmacotherapy of rheumatoid arthritis. 1995 , 20, 131-47		2
407	Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. 1995 , 38, 1466-74		104
406	A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis. 1995 , 14, 531-6		7
405	Management of rheumatoid arthritis. 1995 , 40, 35-6		
404	IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression?. 1995 , 24, 146-53		56
403	New perspectives on treating rheumatoid arthritis. 1995 , 333, 183-4		7
402	Clinical Efficacy of Sulphasalazine--a Review. <i>Rheumatology</i> , 1995 , XXXIV, 35-39	3.9	10
401	Clinical Efficacy of Sulphasalazine--a Review. <i>Rheumatology</i> , 1995 , XXXIV, 35-39	3.9	3
400	The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. 1995 , 333, 142-6		631
399	Category III Symptom-Modifying Antirheumatic Drugs. 1995 , 3, 196-217		6
398	Disease-modifying antirheumatic drugs. Potential effects in older patients. 1995 , 7, 420-37		21
397	Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. 1995 , 50, 137-56		71
396	The Use of Slower-Acting (Class III) Symptom-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. 1996 , 5, 309-325		
395	Role of antimalarials in rheumatoid arthritis [The British experience]. 1996 , 5, 37-40		1
394	Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. 1996 , 10, 435-53		212
393	Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. 1996 , 39, 34-40		1258
392	Guidelines for the management of rheumatoid arthritis. 1996 , 39, 713-722		276
391	Should patients with recent onset rheumatoid arthritis be offered genetic screening?. <i>Annals of the Rheumatic Diseases</i> , 1996 , 55, 407-10	2.4	11

390	Low dose desensitisation does not reduce the toxicity of sulphasalazine in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1996 , 55, 328-30	2.4	2
389	Treatment of rheumatoid arthritis. 1997 , 81, 57-84		9
388	Rheumatoid Arthritis. 1997 , 1, 141-153		5
387	Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. <i>Lancet, The</i> , 1997 , 350, 309-18	40	801
386	The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. 1997 , 29, 127-50		90
385	Evaluation of early rheumatoid arthritis disease activity and outcome. 1997 , 11, 49-63		17
384	Specialist management: needs and benefits. 1997 , 11, 97-107		9
383	Clinical guidelines for management. 1997 , 11, 157-79		8
382	Minocycline in rheumatoid arthritis. 1997 , 40, 794-6		15
381	Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. 1998 , 41, 808-16		158
380	Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. 1998 , 41, 1845-50		591
379	Early, aggressive therapy for rheumatoid arthritis?. 1998 , 11, 5-8		
378	Mutual antagonism of rheumatoid arthritis and hay fever; a role for type 1/type 2 T cell balance. <i>Annals of the Rheumatic Diseases</i> , 1998 , 57, 275-80	2.4	54
377	Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1998 , 57, 146-51	2.4	98
376	Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. <i>Rheumatology</i> , 1999 , 38, 941-7	3.9	162
375	Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. <i>Rheumatology</i> , 1999 , 38, 1213-20	3.9	90
374	Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis. 1999 , 13, 689-700		5
373	Disease modification in rheumatoid arthritis with leflunomide. 1999 , 112, 9-14		6

372	Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. <i>Lancet, The</i> , 1999 , 353, 259-66	4.0	588
371	Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. <i>Annals of the Rheumatic Diseases</i> , 1999 , 58, 220-5	2.4	168
370	Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. 1999 , 131, 768-74		84
369	The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. 2000 , 43, 155-63		1075
368	Rheumatoid Arthritis. 2000 , 674-685		4
367	Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. <i>Annals of the Rheumatic Diseases</i> , 2000 , 59, 468-77	2.4	47
366	The course of rheumatoid arthritis and predictors of psychological, physical and radiographic outcome after 5 years of follow-up. <i>Rheumatology</i> , 2000 , 39, 732-41	3.9	62
365	Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2000 , 59, 504-5	2.4	41
364	Familial vs sporadic rheumatoid arthritis (RA). A prospective study in an early RA inception cohort. <i>Rheumatology</i> , 2000 , 39, 267-73	3.9	22
363	Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. 2000 , 343, 1594-602		2590
362	Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. 2001 , 111, 446-51		434
361	Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. <i>Rheumatology</i> , 2001 , 40, 1231-7	3.9	23
360	Relationship between bone mineral density and radiologic scores of hands in rheumatoid arthritis. 2001 , 4, 263-9		17
359	A clinical and economic review of disease-modifying antirheumatic drugs. 2001 , 19, 715-28		27
358	Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. 2001 , 8, 123-43		36
357	Anti-TNF agents for rheumatoid arthritis. 2001 , 51, 201-8		85
356	Early rheumatoid arthritis: can we predict its outcome?. 2001 , 31, 168-80		12
355	Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. 2001 , 44, 1736-43		211

354	The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. 2001 , 44, 2009-17		370
353	Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. 2001 , 44, 2242-6		61
352	Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy. 2001 , 44, 2703-4		14
351	Étude prospective du squelette de la main par densitométrie à rayons X et par ultrasons, chez les sujets atteints de polyarthrite rhumatoïde récente. 2001 , 68, 40-48		
350	Modified sharp method: factors influencing reproducibility and variability. 2001 , 31, 176-90		15
349	How can the risk of long-term consequences of rheumatoid arthritis be reduced?. 2001 , 15, 139-70		21
348	Prospective X-ray densitometry and ultrasonography study of the hand bones of patients with rheumatoid arthritis of recent onset. 2001 , 68, 34-42		21
347	Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. <i>Annals of the Rheumatic Diseases</i> , 2001 , 60, 913-23	2.4	108
346	Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2001 , 60, 453-8	2.4	40
345	Association of clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in rheumatoid arthritis. <i>Rheumatology</i> , 2001 , 40, 1243-55	3.9	16
344	Rheumatoid factor measured by fluoroimmunoassay: a responsive measure of rheumatoid arthritis disease activity that is associated with joint damage. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 603-7	2.4	22
343	Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 311-8	2.4	114
342	Prevention or retardation of joint damage in rheumatoid arthritis: issues of definition, evaluation and interpretation of plain radiographs. 2002 , 62, 1717-24		6
341	Structural damage in rheumatoid arthritis as visualized through radiographs. 2002 , 4 Suppl 2, S29-33		7
340	COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. 2002 , 46, 347-56		400
339	How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. 2002 , 46, 357-65		540
338	Guidelines for the management of rheumatoid arthritis: 2002 Update. 2002 , 46, 328-46		1135
337	Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. 2002 , 46, 899-905		52

336	Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. 2002 , 46, 906-12		146
335	Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. 2002 , 46, 1196-201		124
334	The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. 2002 , 46, 1451-9		356
333	Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: Association with severity and progression of rheumatoid arthritis in a prospective study. 2002 , 46, 1754-62		41
332	Molecular mechanisms of sulfasalazine-induced T-cell apoptosis. 2002 , 137, 608-20		32
331	Pharmacological treatment of established rheumatoid arthritis. 2003 , 17, 811-29		22
330	Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. 2003 , 48, 1841-8		56
329	Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. 2003 , 48, 1814-27		342
328	Therapeutic strategies for rheumatoid arthritis. 2003 , 2, 473-88		584
327	Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease. 2003 , 3, 351-60		20
326	Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 1094-9	2.4	99
325	Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 611-6	2.4	142
324	Interpreting radiographic data in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 597-604		49
323	Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 120-6	2.4	307
322	Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 675-80	2.4	93
321	HLA-DMA*0103 and HLA-DMB*0104 alleles as novel prognostic factors in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1581-6	2.4	15
320	Evaluation of metacarpophalangeal joint synovitis in rheumatoid arthritis by power Doppler technique: relationship between synovial vascularization and periarticular bone mineral density. 2004 , 71, 384-8		18
319	Quantification of radiological damage in inflammatory arthritis: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. 2004 , 18, 847-60		21

318	N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. 2004 , 21, 324-9		28
317	Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. 2004 , 50, 36-42		295
316	Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. 2004 , 50, 1390-9		71
315	Classifying structural joint damage in rheumatoid arthritis as progressive or nonprogressive using a composite definition of joint radiographic change: a preliminary proposal. 2004 , 50, 1083-96		18
314	Reply. 2004 , 50, 3397-3398		
313	Évaluation de la synovite rhumatoïde des articulations métacarpophalangiennes par échodoppler pulsé relations entre vascularisation synoviale et densité osseuse périarticulaire. 2004 , 71, 763-767		
312	Measurement of structural abnormalities in arthritis using radiographic images. 2004 , 42, 109-19		12
311	Evidence for early disease-modifying drugs in rheumatoid arthritis. 2004 , 6, 15-18		5
310	Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. <i>Lancet, The</i> , 2004 , 363, 675-81	40	1454
309	Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. <i>Rheumatology</i> , 2005 , 44, 280-6	3-9	74
308	Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study. 2005 , 52, 49-60		77
307	Uncoupling of inflammation and destruction in rheumatoid arthritis: myth or reality?. 2005 , 52, 995-9		31
306	Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. 2005 , 52, 1020-30		340
305	Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis. 2005 , 52, 1999-2002		110
304	The smallest detectable difference and sensitivity to change of magnetic resonance imaging and radiographic scoring of structural joint damage in rheumatoid arthritis finger, wrist, and toe joints: a comparison of the OMERACT rheumatoid arthritis magnetic resonance imaging score applied to different joint combinations and the Sharp/van der Heijde radiographic score. 2005 , 52, 2300-6		99
303	Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score. 2005 , 52, 2865-72		44
302	Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. 2005 , 52, 3020-9		184
301	Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?. 2005 , 52, 2975-83		63

300	Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. 2005 , 52, 3381-90		1009
299	Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. 2005 , 52, 3371-80		215
298	Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. 2005 , 52, 3898-909		69
297	Progress toward the cure of rheumatoid arthritis? The BeSt study. 2005 , 52, 3326-32		23
296	A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 38-43	2.4	49
295	Tratamiento de la artritis reumatoide. 2005 , 9, 1822-1829		
294	Sulfasalazine. 2005 , 93-132		
293	The evidence for early intervention. 2005 , 31, 575-89		20
292	Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. 2005 , 65, 661-94		77
291	Sulfasalazine: a review of its use in the management of rheumatoid arthritis. 2005 , 65, 1825-49		121
290	Radiografía simple y artritis reumatoide. Lectura sistemática de la progresión radiológica y aplicaciones. 2005 , 6, 103-112		
289	Has rheumatoid arthritis become a milder disease?. 2005 , 2, 331-336		1
288	Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. 2006 , 8, R31		45
287	The definition and measurement of disease modification in inflammatory rheumatic diseases. 2006 , 32, 9-44, vii		87
286	Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. 2006 , 54, 702-10		336
285	A critical appraisal of radiographic scoring systems for assessment of juvenile idiopathic arthritis. 2006 , 36, 759-72		36
284	Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. 2006 , 54, 1063-74		407
283	Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. 2006 , 54, 1087-95		164

282	Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. 2006 , 54, 1151-64		77
281	Extremity magnetic resonance imaging in rheumatoid arthritis: report of the American College of Rheumatology Extremity Magnetic Resonance Imaging Task Force. 2006 , 54, 1034-47		22
280	Variation in radiologic joint destruction in rheumatoid arthritis differs between monozygotic and dizygotic twins and pairs of unrelated patients. 2006 , 54, 2028-30		28
279	The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. 2006 , 54, 1772-7		141
278	Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. 2006 , 54, 2830-9		107
277	Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. 2006 , 54, 2784-92		205
276	Reply. 2006 , 54, 2339-2339		2
275	Use of biologics in rheumatoid arthritis: where are we going?. 2006 , 63, S19-41		15
274	Rheumatoid Arthritis and the Skin. 2006 , 161-183		
273	Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. 2006 , 35, 175-81		75
272	Joint surgery in the Utrecht Rheumatoid Arthritis Cohort: the effect of treatment strategy. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 1506-11	2.4	32
271	Comparison of the Health Assessment Questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2006 , 45, 454-8	3.9	64
270	InforMatrix: treatment of rheumatoid arthritis using biologics. 2006 , 7, 1769-89		2
269	Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 1357-62	2.4	81
268	The clinical application of etanercept in Chinese patients with rheumatic diseases. <i>Modern Rheumatology</i> , 2006 , 16, 206-213	3.3	14
267	Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 893-9 ⁴	2.4	81
266	Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. <i>Modern Rheumatology</i> , 2007 , 17, 1-9	3.3	60
265	Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial—an Indian experience. 2007 , 23, 2227-34		14

264	Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 651-7	2.4	11
263	A vital clue to deciphering bone pathology: MRI bone oedema in rheumatoid arthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1549-52	2.4	34
262	Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1093-7	2.4	99
261	Radiological damage in patients with rheumatoid arthritis on sustained remission. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 358-63	2.4	85
260	Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1334-8	2.4	17
259	Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1443-9	2.4	372
258	New therapies for treatment of rheumatoid arthritis. <i>Lancet, The</i> , 2007 , 370, 1861-74	4.0	706
257	Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis. 2007 , 9, R62		14
256	Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. 2007 , 56, 489-97		144
255	Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. 2007 , 56, 2698-707		143
254	Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. 2007 , 56, 3087-95		71
253	Validation of a radiographic damage index in chronic gout. 2007 , 57, 1067-73		80
252	Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. 2007 , 56, 3928-39		171
251	Flexor Hallucis Longus tendon rupture in RA-patients is associated with MTP 1 damage and pes planus. 2007 , 8, 110		12
250	Management of established rheumatoid arthritis with an emphasis on pharmacotherapy. 2007 , 21, 43-57		4
249	Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. 2007 , 124, 158-64		65
248	Course of damage to the hallux over 5 years after forefoot resection arthroplasty in rheumatoid arthritis patients. 2007 , 31, 477-81		6
247	The burden of rheumatoid arthritis and access to treatment: a medical overview. 2008 , 8 Suppl 2, S39-47		16

246	Biomarkers in the prediction of radiographic progression in early rheumatoid arthritis: comment on the article by Young-Min et al. 2008 , 58, 1558-9; author reply 1559		2
245	Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. 2008 , 58, 1293-8		88
244	Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. 2008 , 58, 1582-9		91
243	Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. 2008 , 59, 510-4		32
242	Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. 2008 , 58, 2248-56		208
241	The importance of reporting disease activity states in rheumatoid arthritis clinical trials. 2008 , 58, 2622-31		39
240	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. 2008 , 58, 3319-29		458
239	Ability of oblique foot radiographs to detect erosions in early arthritis: results in the ESPOIR cohort. 2008 , 59, 1729-34		27
238	Issues in the design of new clinical trials for rheumatoid arthritis therapeutics. 2008 , 4, 641-8		7
237	Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. 2008 , 10, R106		87
236	Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. <i>Lancet, The</i> , 2008 , 372, 375-82	40	625
235	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. <i>Modern Rheumatology</i> , 2008 , 18, 460-464	33	41
234	Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis. 2008 , 4, 296-7		3
233	Anakinra for rheumatoid arthritis. 2008 ,		3
232	The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life. 2009 , 1, 95-106		2
231	Radiography. 2009 , 260-266		1
230	Testing an OMERACT MRI scoring system for peripheral psoriatic arthritis in cross-sectional and longitudinal settings. 2009 , 36, 1811-5		26
229	Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients. <i>Modern Rheumatology</i> , 2009 , 19, 513-521	33	2

228	A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. <i>Rheumatology</i> , 2009 , 48, 1114-21	3.9	173
227	Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1535-40	2.4	43
226	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. 2009 , 8, 274-80		89
225	What have we learnt about the development and progression of early RA from RCTs?. 2009 , 23, 13-24		5
224	Ten years of infliximab: insights from clinical trials in rheumatoid arthritis. 2009 , 623 Suppl 1, S5-9		3
223	Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. 2009 , 60, 1242-9		99
222	Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.		334
221	Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis. 2009 , 28, 1135-9		12
220	Sulphasalazine accelerates apoptosis in neutrophils exposed to immune complex: Role of caspase pathway. 2009 , 36, 1132-5		7
219	The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. 2009 , 7, 25		213
218	Anakinra for rheumatoid arthritis. 2009 , CD005121		94
217	Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. 2009 , 26, 273-93		19
216	Clinical approaches to early inflammatory arthritis. 2009 , 5, 627-33		6
215	Biologics for rheumatoid arthritis: an overview of Cochrane reviews. 2009 , CD007848		115
214	Anakinra for rheumatoid arthritis: a systematic review. 2009 , 36, 1118-25		233
213	Biologics for rheumatoid arthritis: an overview of Cochrane reviews. 2009 ,		60
212	Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab. <i>Modern Rheumatology</i> , 2010 , 20, 561-565	3.3	4
211	Tocilizumab for rheumatoid arthritis. 2010 ,		18

210	Tocilizumab for rheumatoid arthritis. 2010 , CD008331		35
209	Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission. 2010 , 29, 87-90		3
208	Radiologic observation: repair of focal bone erosions after humanized antitumor necrosis factor antibody adalimumab therapy in a patient with rheumatoid arthritis. 2010 , 29, 211-3		12
207	Pain Associated with Rheumatoid Arthritis. 2010 , 106-120		
206	Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. 2010 , 62, 108-17		56
205	Radiographic severity of rheumatoid arthritis in African Americans: results from a multicenter observational study. 2010 , 62, 624-31		26
204	Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. 2010 , 62, 674-82		92
203	Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. 2010 , 62, 2852-63		92
202	Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. 2010 , 4, 263-78		64
201	Golimumab for rheumatoid arthritis: a systematic review. 2010 , 37, 1096-104		21
200	Radiographic progression of cervical lesions in patients with rheumatoid arthritis receiving infliximab treatment. <i>Modern Rheumatology</i> , 2010 , 20, 273-279	3-3	11
199	Golimumab for rheumatoid arthritis. 2010 , CD008341		27
198	Certolizumab pegol: a new biologic targeting rheumatoid arthritis. 2010 , 6, 855-66		15
197	The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis. 2010 , 10, 773-86		6
196	The efficacy and safety of golimumab in the treatment of arthritis. 2010 , 10, 1131-43		2
195	Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis. 2010 , 12, R75		17
194	Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. 2011 , 38, 10-20		104
193	The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial. 2011 , 13, R70		7

192	Certolizumab in the long-term treatment of rheumatoid arthritis. 2011 , 3, 63-71		1
191	Investigation on Brazilian clinical practices in rheumatoid arthritis: the Brazilian rheumatoid arthritis clinical practices investigation--BRACTICE. 2011 , 17, S1-10		2
190	Comparison of the Genant-modified Sharp and van der Heijde-modified Sharp scoring methods for radiographic assessment in rheumatoid arthritis. 2011 , 6, 15-24		13
189	[Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 2. Salazosulfapyridine]. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2011 , 100, 2910-7	0	2
188	An overview of commonly used radiographic scoring methods in rheumatoid arthritis clinical trials. 2011 , 30, 1-6		23
187	Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study. 2011 , 30, 1589-93		29
186	Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis. 2011 , 12, 120		28
185	Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. 2011 , 63, 37-42		168
184	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. 2011 , 63, 573-86		520
183	Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis. 2011 , 63, 662-9		23
182	The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. 2011 , 63, 1200-10		90
181	Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. 2011 , 63, 1265-73		41
180	Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. 2011 , 63, 3712-22		71
179	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—multicenter, double-blind, parallel-group trial. <i>Modern Rheumatology</i> , 2011 , 21, 458-468	3.3	21
178	Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 2126-30	2.4	28
177	Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. <i>Rheumatology</i> , 2012 , 51, 1628-38	3.9	35
176	Bone marrow edema and osteitis in rheumatoid arthritis: the imaging perspective. 2012 , 14, 224		53
175	Volume measurement of bone erosions in magnetic resonance images of patients with rheumatoid arthritis. 2012 , 67, 814-23		11

174	Predictors of functional impairment and pain in erosive osteoarthritis of the interphalangeal joints: comparison with controlled inflammatory arthritis. 2012 , 64, 1430-6	32
173	Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. 2012 , 15, 188-96	27
172	Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. 2012 , 64, 67-76	165
171	Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. 2012 , 64, 350-9	50
170	Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. 2012 , 64, 360-70	49
169	Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?. 2013 , 24, 1429-36	47
168	Baseline anti-citrullinated peptide antibody (ACPA) titers and serum interleukin-6 (IL-6) levels possibly predict progression of bone destruction in early stages of rheumatoid arthritis (ERA). 2013 , 33, 451-6	12
167	Imaging in early rheumatoid arthritis. 2013 , 27, 499-522	35
166	Missing radiographic data handling in randomized clinical trials in rheumatoid arthritis. 2013 , 23, 1435-52	3
165	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. 2013 , 65, 28-38	186
164	Association of genetic variants in the IL4 and IL4R genes with the severity of joint damage in rheumatoid arthritis: a study in seven cohorts. 2013 , 65, 3051-7	19
163	Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate. 2013 , 2013, 457876	14
162	Do radiographic joint damage and disease activity influence functional disability through different mechanisms? Direct and indirect effects of disease activity in established rheumatoid arthritis. 2013 , 40, 1505-12	7
161	Current immunotherapy in rheumatoid arthritis. 2013 , 5, 955-74	79
160	Potential classification criteria for rheumatoid arthritis after two years: results from a French multicenter cohort. 2013 , 65, 1227-34	14
159	First-year radiographic progression as a predictor of further progression in early arthritis: results of a large national French cohort. 2013 , 65, 1907-15	28
158	Imaging in rheumatology. 2013 , 22, 20120008	
157	Does a genetic variant in FOXO3A predict a milder course of rheumatoid arthritis?. 2014 , 66, 1678-81	5

156	Feasibility, reliability, and sensitivity to change of four radiographic scoring methods in patients with psoriatic arthritis. 2014 , 66, 311-7		19
155	Frequency of radiographic damage and progression in individual joints in children with juvenile idiopathic arthritis. 2014 , 66, 27-33		7
154	Generalization and extrapolation of treatment effects from clinical studies in rheumatoid arthritis. 2014 , 66, 998-1007		4
153	Insights into rheumatoid arthritis from use of MRI. 2014 , 16, 388		10
152	Prevalence and concordance of early and sustained remission assessed by various validated indices in the early arthritis "ESPOIR" cohort. 2014 , 81, 409-15		17
151	Association of anticyclic citrullinated peptide antibodies and/or rheumatoid factor status and clinical presentation in early arthritis: results from the ESPOIR cohort. 2014 , 41, 1614-22		12
150	High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. <i>Rheumatology</i> , 2014 , 53, 1886-95	3.9	48
149	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 86-94	2.4	197
148	A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated inflammatory arthritis: study protocol for a randomized controlled trial. 2014 , 15, 268		3
147	Exploring cartilage damage in gout using 3-T MRI: distribution and associations with joint inflammation and tophus deposition. 2014 , 43, 917-24		23
146	MRI osteitis predicts cartilage damage at the wrist in RA: a three-year prospective 3T MRI study examining cartilage damage. 2014 , 16, R33		20
145	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 492-509	2.4	1487
144	Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 391-5	2.4	33
143	Imaging in the crystal arthropathies. 2014 , 40, 231-49		19
142	A comparative MRI study of cartilage damage in gout versus rheumatoid arthritis. 2015 , 59, 431-435		3
141	Subcutaneous or intramuscular methotrexate for rheumatoid arthritis. 2015 ,		
140	Asymptomatic atherosclerosis in egyptian rheumatoid arthritis patients and its relation to disease activity. 2015 , 2015, 381931		7
139	Prévalence et concordance de la rémission précoce et prolongée évaluée par différents indices validés de la cohorte d'arthrites débutantes « ESPOIR ». 2015 , 82, 47-53		

138	Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts. <i>Modern Rheumatology</i> , 2015 , 25, 38-42	3.3	8
137	Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides. 2015 , 17, 2		13
136	Lymphopenia in early arthritis: Impact on diagnosis and 3-year outcomes (ESPOIR cohort). 2015 , 82, 417-22		2
135	Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects. 2015 , 64, 647-59		12
134	Expression of Interferon- γ Receptor Genes in Peripheral Blood Mononuclear Cells Is Associated With Rheumatoid Arthritis and Its Radiographic Severity in African Americans. 2015 , 67, 1165-70		13
133	Early therapeutic intervention with methotrexate prevents the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis: A prospective cohort study. <i>Modern Rheumatology</i> , 2015 , 25, 831-6	3.3	8
132	Evaluation of magnetic resonance imaging-detected tenosynovitis in the hand and wrist in early arthritis. 2015 , 67, 869-76		44
131	Imaging in rheumatoid arthritis: options, uses and optimization. 2015 , 11, 1131-46		10
130	2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis. 2015 , 11, 279-294		3
129	Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. 2015 , 23, 231-69		300
128	2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. <i>Reumatología Clínica</i> , 2015 , 11, 279-94	0.9	60
127	Further Simplification of the Simple Erosion Narrowing Score With Item Response Theory Methodology. 2016 , 68, 1206-10		3
126	Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis. 2016 , 2, e000205		9
125	Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1043-50	2.4	129
124	Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. 2016 , 2, e000210		2
123	Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans. 2016 , 18, 241		23
122	One-year maintenance with routine assessment of patient index data 3-based remission may inhibit radiographic progression in patients with rheumatoid arthritis treated with routine clinical therapy: A retrospective comparison of radiographic outcome and its prognostic factors between maintained remissions with patient-reported outcome index and physician-oriented disease activity indices. <i>Modern Rheumatology</i> , 2016 , 26, 833-41	3.3	2
121	Platelet-Derived Growth Factor Receptor Activation Promotes the Prodestructive Invadosome-Forming Phenotype of Synoviocytes from Patients with Rheumatoid Arthritis. 2016 , 196, 3264-75		28

120	Erosive and osteoarthritic structural progression in early rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 1477-88	3.9	12
119	Structural damage in rheumatoid arthritis: comparison between tendon damage evaluated by ultrasound and radiographic damage. <i>Rheumatology</i> , 2016 , 55, 1042-6	3.9	9
118	Rheumatoid arthritis. <i>Lancet, The</i> , 2016 , 388, 2023-2038	40	1794
117	La lymphopénie dans la polyarthrite débutante : impact sur le diagnostic et les résultats à 3 ans (la cohorte Espoir). 2016 , 83, 358-363		
116	Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). 2016 , 11, CD012437		18
115	Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. 2016 , 18, 226		68
114	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. 2016 , 17, 461		15
113	Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. 2016 , CD012183		36
112	Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab. 2016 , 45, 274-81		24
111	Snail Is a Critical Mediator of Invadosome Formation and Joint Degradation in Arthritis. 2016 , 186, 359-74		11
110	Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 327-34	3.9	11
109	Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis. 2016 , 12, 319-26		3
108	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 75-83	2.4	66
107	The growth factor midkine may play a pathophysiological role in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2017 , 27, 54-59	3.3	19
106	Multireader assessment as an alternative to reference assessment to improve the detection of radiographic progression in a large longitudinal cohort of rheumatoid arthritis (ESPOIR). 2017 , 3, e000343		4
105	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. 2017 , 3, CD012591		29
104	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. 2017 , 45, 1058-1072		35
103	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1348-1356	2.4	25

102	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. 2017 , 5, CD012657		33
101	Predictor of Hand Radiological Progression in Patients With Rheumatoid Arthritis Receiving TNF Antagonist Therapy by Change in Grayscale Synovitis-A Preliminary Study. 2017 , 23, 73-76		2
100	Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1432-1435	2.4	17
99	Managing rheumatic and musculoskeletal diseases - past, present and future. 2017 , 13, 443-448		74
98	Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. 2017 , 69, 1741-1750		24
97	Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy. 2017 , 20, 1468-1480		6
96	Time-averaged disease activity fits better joint destruction in rheumatoid arthritis. 2017 , 7, 5856		5
95	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. 2017 , 69, 1937-1948		21
94	Computer-aided diagnosis system for Rheumatoid Arthritis using machine learning. 2017 ,		9
93	Automated estimation of mTS score in hand joint X-ray image using machine learning. 2017 ,		1
92	Assessment of 3-month changes in bone microstructure under anti-TNF α therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT). 2017 , 19, 222		18
91	Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis. 2017 , 19, 241		2
90	Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results. 2018 , 70, 832-840		74
89	Mavrimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor β Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis. 2018 , 70, 679-689		53
88	Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results. 2018 , 12, 171-182		4
87	Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. 2018 , 158, 502-516		155
86	Influence of pain score measured by a visual analog scale (PS-VAS) on the Health Assessment Questionnaire Disability Index and 28-joint Disease Activity Index with C-reactive protein in rheumatoid arthritis patients. 2018 , 21, 1955-1961		8
85	Co-expression of CD21L and IL17A defines a subset of rheumatoid synovia, characterised by large lymphoid aggregates and high inflammation. <i>PLoS ONE</i> , 2018 , 13, e0202135	3.7	5

84	Validity of adopting a Health Assessment Questionnaire Disability Index less than 0.5 as a target in elderly rheumatoid arthritis patients. 2019 , 38, 3351-3360		4
83	Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). 2019 , 6, 559-571		7
82	Tai Chi for rheumatoid arthritis. 2019 , 9, CD004849		6
81	Treat to Target in Rheumatology: A Historical Account on Occasion of the 10th Anniversary. 2019 , 45, 477-485		14
80	Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort. 2019 , 21, 140		13
79	Detection of Fine Radiographic Progression in Finger Joint Space Narrowing Beyond Human Eyes: Phantom Experiment and Clinical Study with Rheumatoid Arthritis Patients. 2019 , 9, 8526		5
78	Diagnostic. 2019 , 163-178		
77	Structural Changes over a Short Period Are Associated with Functional Assessments in Rheumatoid Arthritis. 2019 , 46, 676-684		9
76	Radiographic scoring methods in rheumatoid arthritis and psoriatic arthritis. 2019 , 124, 1071-1086		12
75	Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort. 2019 , 21, 243		5
74	Development and validation of a deep-learning model for scoring of radiographic finger joint destruction in rheumatoid arthritis. 2019 , 3, rkz047		11
73	Magnetic resonance imaging of the craniovertebral junction in early rheumatoid arthritis. 2019 , 48, 553-561		12
72	Association of Baseline Peptidylarginine Deiminase 4 Autoantibodies With Favorable Response to Treatment Escalation in Rheumatoid Arthritis. 2019 , 71, 696-702		11
71	Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice. <i>Modern Rheumatology</i> , 2020 , 30, 807-815	3.3	2
70	Clinical and Structural Efficacy of Hydroxychloroquine in Rheumatoid Arthritis: A Systematic Review. 2020 , 72, 36-40		16
69	EULAR definition of "arthralgia suspicious for progression to rheumatoid arthritis" in a large cohort of patients included in a program for rapid diagnosis: role of auto-antibodies and ultrasound. 2020 , 39, 1493-1499		8
68	Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. <i>Rheumatology</i> , 2020 , 59, 2090-2098	3.9	6
67	Finger Joint Detection Method in Hand X-ray Radiograph Images Using Statistical Shape Model and Support Vector Machine. 2020 ,		2

66	Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. 2020 , 25,		2
65	Elevated serum granzyme B levels are associated with disease activity and joint damage in patients with rheumatoid arthritis. 2020 , 48, 300060520962954		3
64	Evaluation of Current Therapies for COVID-19 Treatment. 2020 , 8,		9
63	Efficacy and safety of intra-articular injection with triamcinolone acetonide for patients with rheumatoid arthritis. 2020 , 36, 404-412		1
62	Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis. 2020 , 21, 2153-2160		2
61	Cortical thickness relative to the transverse diameter of third metacarpal bone reflects bone mineral density in patients with rheumatoid arthritis. <i>Bone</i> , 2020 , 137, 115405	4-7	3
60	Effect of antiresorptive and bone forming treatments in bone erosions in rheumatoid arthritis. 2020 , 154, 358-365		
59	[Management of early rheumatoid arthritis : Interdisciplinary guideline]. 2020 , 79, 1-38		11
58	Noninferiority Trials to Evaluate Drug Effects in Rheumatoid Arthritis. 2020 , 72, 1258-1265		1
57	Association Between Vitamin D Deficiency and Disease Activity, Disability, and Radiographic Progression in Early Rheumatoid Arthritis: The ESPOIR Cohort. 2020 , 47, 1624-1628		7
56	Outcomes Reported in Prospective Long-Term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review. 2021 , 73, 649-657		2
55	Finger Joint Cartilage Evaluated by Semiquantitative Ultrasound Score in Patients With Rheumatoid Arthritis. 2021 , 73, 173-179		1
54	Real-World Methotrexate Dose on Clinical Effectiveness and Structural Damage of Certolizumab Pegol With Rheumatoid Arthritis. 2021 , 8, 643459		1
53	Sind röntgenologische Scoring-Methoden als Parameter zur Verlaufsbeurteilung der rheumatoiden Arthritis noch zeitgemäß? 2021 , 46, 149-154		
52	Bisphosphonates in inflammatory rheumatic diseases. <i>Bone</i> , 2021 , 146, 115887	4-7	1
51	Analytical Methodologies for Determination of Hydroxychloroquine and Its Metabolites in Pharmaceutical, Biological and Environmental Samples. 2021 , 17,		0
50	Radiographic changes in the temporomandibular joint related to medication in rheumatic diseases. 2021 , 50, 20200557		
49	Early and advanced stages in palindromic rheumatism patients: Test characteristics of three classification criteria and discrimination potential. 2022 , 44, 63-67		

48	Juvenile Rheumatoid Arthritis. 1993 , 231-359		6
47	Radiographic Imaging End Points in Rheumatoid Arthritis Trials. 2008 , 201-221		2
46	The Metrics and New Imaging Marker Qualification in Medical Imaging Modalities. 2014 , 27-45		1
45	Scoringmethoden bei der rheumatoiden Arthritis. 2007 , 27-46		2
44	The clinical application of etanercept in Chinese patients with rheumatic diseases. <i>Modern Rheumatology</i> , 2006 , 16, 206-13	3-3	10
43	Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. <i>Modern Rheumatology</i> , 2007 , 17, 1-9	3-3	30
42	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. <i>Modern Rheumatology</i> , 2008 , 18, 460-4	3-3	24
41	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs--a multicenter, double-blind, parallel-group trial. <i>Modern Rheumatology</i> , 2011 , 21, 458-68	3-3	10
40	Treatment of Rheumatoid Arthritis. 2009 , 1119-1143		4
39	Effect of antiresorptive and bone forming treatments in bone erosions in rheumatoid arthritis. <i>Medicina Clínica</i> , 2020 , 154, 358-365	1	1
38	In anti-CCP+ at-risk individuals, radiographic bone erosions are uncommon and are not associated with the development of clinical arthritis. <i>Rheumatology</i> , 2021 , 60, 3156-3164	3-9	2
37	Contribution of bacterial pathogens to evoking serological disease markers and aggravating disease activity in rheumatoid arthritis. <i>PLoS ONE</i> , 2018 , 13, e0190588	3-7	5
36	Risk Factors Associated With Short-term Clinical Results After Total Hip Arthroplasty for Patients With Rheumatoid Arthritis. <i>Orthopedics</i> , 2018 , 41, e772-e776	1-5	5
35	Brachial artery flow-mediated dilation and carotid intima-media thickness for assessment of subclinical atherosclerosis in rheumatoid arthritis. <i>The Egyptian Journal of Internal Medicine</i> , 2017 , 29, 132-140	0-5	2
34	Rheumatic Diseases. 2001 , 271-311		
33	Evaluation and outcomes of patients with rheumatoid arthritis. 2011 , 941-954.e1		1
32	Imaging in Musculoskeletal, Metabolic, Endocrinological, and Pediatric Clinical Trials. 2014 , 237-251		
31	Rational Usage of Disease Modifying Anti-Rheumatic Drugs with the Guidance of EULAR and ACR Suggestions. <i>Open Journal of Rheumatology and Autoimmune Diseases</i> , 2015 , 05, 104-112	0-2	

30	Evaluation and outcomes of patients with rheumatoid arthritis. 2015 , 790-801		1
29	A 16-week multicenter observational study of the efficiency and safety of rheumatoid arthritis therapy with methotrexate. <i>Sovremennaya Revmatologiya</i> , 2018 , 12, 106-111	0.7	
28	Infliximab in rheumatology. 2006 , 65-81		
27	Historical and Current Perspectives on Management of Osteoarthritis and Rheumatoid Arthritis. 2008 , 5-36		1
26	Development of Biological Therapies for Inflammatory Arthritis. 2008 , 37-49		
25	Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients. <i>Modern Rheumatology</i> , 2009 , 19, 513-21	3.3	
24	Radiographic progression of cervical lesions in patients with rheumatoid arthritis receiving infliximab treatment. <i>Modern Rheumatology</i> , 2010 , 20, 273-9	3.3	2
23	Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab. <i>Modern Rheumatology</i> , 2010 , 20, 561-5	3.3	3
22	Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. <i>Annals of the Rheumatic Diseases</i> , 2001 , 60, 817-27	2.4	93
21	Rheumatoid arthritis. <i>Clinical Evidence</i> , 2007 , 2007,		1
20	Guidelines and audit measures for the specialist supervision of patients with rheumatoid arthritis. Report of a Joint Working Group of the British Society for Rheumatology and the Research Unit of the Royal College of Physicians. <i>Journal of the Royal College of Physicians of London</i> , 1992 , 26, 76-82		19
19	Bone fragility via degradation of bone quality featured by collagen/apatite micro-arrangement in human rheumatic arthritis. <i>Bone</i> , 2021 , 155, 116261	4.7	3
18	Pursuit and New Trend in Rheumatoid Arthritis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020 , 109, 1669-1684	0	
17	Damage in Hidradenitis Suppurativa: A Narrative Review Emphasizing the Need for a Novel Outcome Measure.. <i>British Journal of Dermatology</i> , 2022 ,	4	0
16	Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	0
15	Physiologically-Based Pharmacokinetics Modeling for Hydroxychloroquine as a Treatment for Malaria and Optimized Dosing Regimens for Different Populations. <i>Journal of Personalized Medicine</i> , 2022 , 12, 796	3.6	0
14	Development of a scoring model for the Sharp/van der Heijde score using convolutional neural networks and its clinical application in predicting radiographic progression using a graph convolutional network.		
13	Ultrasound tenosynovitis: A differential feature of patients with seronegative rheumatoid arthritis. <i>Reumatologia Clínica</i> , 2022 ,	0.9	

12	Women in rheumatology: major contributions and key discoveries of the XX century. <i>Rheumatology</i> , 3.9	0
11	SCORING RADIOGRAPHIC ABNORMALITIES IN RHEUMATOID ARTHRITIS. 1996 , 34, 233-241	4
10	Environmental and ecotoxicological effects of drugs used for the treatment of COVID 19. 10,	0
9	Synthesis of Reduced Graphene Oxide by Ethyl Acetate and Its Utilization in Determining Hydroxychloroquine in Wastewater and Pharmaceutical Samples. 2022 , 7,	0
8	Deep learning-based automatic-bone-destruction-evaluation system using contextual information from other joints. 2022 , 24,	0
7	Development of a scoring model for the Sharp/van der Heijde score using convolutional neural networks and its clinical application.	0
6	Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA).	0
5	Métricas em artrite reumatoide: uma revisão para a prática clínica. 2022 , 9-13	0
4	Artificial intelligence and the future of radiographic scoring in rheumatoid arthritis: a viewpoint. 2022 , 24,	0
3	Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM.	0
2	Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort. 1-9	1
1	Ultrasound tenosynovitis: A differential feature of patients with seronegative rheumatoid arthritis. 2023 , 19, 63-66	0